Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a website empower endometrial cancer patients?

NCT ID NCT07739745

Knowledge-focused Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This study aims to develop an online educational tool for women diagnosed with endometrial cancer. Participants will use a website to access educational content, complete surveys, and provide feedback on its usability. The goal is to create a resource that can be made widely available to help patients better understand their condition and treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Interactive educational website
What this could lead to
If successful, this could provide a widely available online resource to help endometrial cancer patients better understand their diagnosis and treatment.
What could go wrong
This is an early-stage study focused on tool development and usability, not on treatment outcomes. The tool may not be effective or widely adopted.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Jun 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients: Study Objective 1 (Part A-C see Figure 2) 1. Women who have been diagnosed with endometrial cancer 2. Must be at least 18 years old 3. Must read and speak English or Spanish 4. Must provide written informed consent Study Objectives 2 and 3 (Pilot Study) 1. Women who have been diagnosed with endometrial cancer who are or will be receiving systemic treatment 2. Must be at least 18 years old 3. Must read and speak English or Spanish 4. Must provide written informed consent. Physicians: Study Objective 1 (Qualitative Interviews) 1. Gynecologic oncologists or medical oncologists who practice at MDA or outside institutions 2. Must be able to speak and read English 3. Must provide written informed consent Healthcare Providers: Study Objectives 2 and 3 (Pilot Study) 1. Healthcare Providers (including but not limited to gynecologic oncologists and APPs) who practice at MDA, the HALs or LBJ Hospital who provide care to women diagnosed with endometrial cancer 2. Must be able to speak and read English 3. Must provide written informed consent Exclusion Criteria: None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endometrial cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrium neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endometrial cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • UT MD Anderson

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.